Roche
ROG
Performance
About Roche
Roche is a leading global healthcare company headquartered in Basel, Switzerland, focused on discovering and delivering medicines and diagnostic tests that improve patient outcomes. The company operates across pharmaceuticals and diagnostics, with research and development spanning cancer care, autoimmune diseases, and digital health solutions to impact patients worldwide. Roche emphasizes scientific excellence, ethical standards, and sustainable practices while advancing product development through innovative pipelines and diagnostics capabilities. It engages in global markets, investor communications, and patient-centered stories to showcase its impact on health outcomes.
Recent News
Roche Insists Amylin Obesity Drug Still Valuable for Patients Who ‘Don’t Want Side Effects’
The Evolving BTK Story in Multiple Sclerosis: Clinical Report
5 FDA Decisions to Watch in the First Quarter of 2026
Biogen Seals $5.3 B Deal for Apellis, Adds Two Blockbuster Drugs
Clinical Trial Failures of 2026
Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall
Roche to Pay $750 Million Upfront for AI Diagnostics Pioneer PathAI
Pfizer and the Broader Push to Improve Cold Chain Visibility
Biotech in 2025: A Retrospective
Zealand Pharma and Roche Advance Petrelintide to Phase 3 for Chronic Weight Management
Roche Secures CE Mark for Elecsys NfL Blood Test to Track MS Neuroinflammation
Is Pharma Missing the Boat on Diagnostics?
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
AstraZeneca, Daiichi Sankyo Win EU CHMP Nod for Enhertu in HER2 Tumors
FDA Grants Priority Review to Ifinatamab Deruxtecan for Treated Small Cell Lung Cancer
The 5 Largest IPOs in Biopharma History
Sanofi MS Drug Rejected in US Gets an Endorsement in Europe
FDA Clears FoundationOne CDx as Companion Diagnostic for Tepotinib in MET‑Exon‑14 NSCLC
Outlook Therapeutics Narrows Q2 Loss, Awaits FDA Decision on LYTENAVA in May 2026
GSK Reports Promising Early Results in Ovarian and Womb Cancer Drug Trial
AstraZeneca and Daiichi Sankyo Secure Earlier‑Line Enhertu Approvals in South Korea
Apple's Expanding Enterprise Footprint to Boost Sales: What's Ahead?
USP Adds Tamiflu, Trulicity to Vulnerable List as Upstream Analysis Reshapes Supply Concerns
AstraZeneca Leads Big Pharma’s AI Clinical Trials Revolution with Real-World Patient Impact
Kelun‑Biotech Shows 87% Response Rate for RET‑Fusion Lung Cancer in Phase II ASCO Data
Lilly Establishes up to $2.7B Repertoire Deal in Second Immune Play of 2026
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Analysis Finds Efficiencies, Savings of Using a Single Bispecific for DLBCL and FL
Nanoparticle Therapy Erases Alzheimer Plaques in Mice, Restores Cognition
Salesforce vs Veeva - the Game's Afoot and the Life Sciences Battleground Is Hotting Up!
AI Pioneers Unite to Launch the Shared AI License Foundation to Advance Foundation Model Innovation
Labcorp Holdings Inc (LH) Q1 2026 Earnings Call Transcript
Tolion Health AI Launches AI-Powered Tolion Brain Coach App for Brain Health, Longevity, and Prevention of Alzheimer’s Disease
UCB to Acquire Candid Therapeutics for $2 B, Adding T‑Cell Engager Platform to Immunology Portfolio
FDA Expands Vyvgart Approval to All Adult Myasthenia Gravis Types
Roche Launches Liver Disease Algorithm Panel
Jazz Pharma’s Ziihera Combos Get FDA Priority Review for First‑line HER2‑positive Gastric Cancer
GSK Moves Ovarian Cancer ADC Mo-Rez Into Five Phase 3 Trials
Pharma and Biotech M&As 2026 Deal Watcher
Deep Dive: Huntington’s at a Crossroads
Roche Returns to Chinese Biotech MediLink for Another ADC Pact
Gepotidacin
Boehringer Drug Scores in Rare Kidney Disease FSGS
Roche's Fenebrutinib Cuts RMS Relapses to One Every 17 Years in Phase III Trials
Fidelity’s Three Low‑Cost ETFs Beat Vanguard Peers on Returns
Up the Ranks: Nokia Welcomes Kristen Pressner as Chief People Officer
As Amyloid Falls Out of Favor, Here’s Where Alzheimer’s R&D Is Headed Next
Akeso's Cadonilimab Shows Survival Gain in Phase II Pancreatic Cancer Trial
Why Owning the Learning Loop Matters More Than Owning the Lab
MS Expert Takes the Helm
Recent Deals
Roche to Acquire PathAI for Up to $1.05B in AI‑Driven Diagnostics Deal
Roche Invests $20M in C4 Therapeutics to Advance DAC Cancer Therapy
Mission Therapeutics Raises $13.3M From Existing Strategic Investors
Roche to Acquire SAGA Diagnostics for Up to $595M